The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19, as outlined in the consultation document.

All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.

Please note

1.    The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to nuth.nyrdtc.rxsupp@nhs.net

2.     This consultation closes at 5pm on Thursday 30th May 2024

Title Documents Decision Date

New

16/05/2024
30 day TA Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 059 NENC 30 day TA Consultation - NICE TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 - May 2024